Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED)

Inclusion Criteria: (Patients must meet each of the following criteria to be eligible for participation in the study). * Male or female patients, ≥ 18 years of age. * Patients with a documented measurable or evaluable malignancy, including myeloma or lymphoma, that is recurrent, advanced, or metastatic. * Patients with disease that is currently refractory to, or not amenable to, standard therapy. * Patients with disease that is currently not amenable to surgical intervention. * Patients with Karnofsky performance status of ≥ 70% (Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1) and an anticipated life expectancy of ≥ 3 months. * Patients either not of childbearing potential, or agreeing to use a medically effective method of contraception. * Patients with the ability to understand and give written informed consent. Exclusion Criteria: (Patients meeting any of the following criteria are ineligible for participation in the study) * Women who are pregnant or lactating. * Patients with primary central nervous system (CNS) malignancies. Patients with leukemia, any form. * Patients with certain hematologic abnormalities. * Patients with certain serum chemistry abnormalities at baseline. * Patients with known or suspected hypersensitivity to either drugs formulated with polysorbate 80 (Tween 80) or any other excipient contained in the test drug formulation. * Patients with known hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin). * Patients with significant cardiovascular disease. * Patients with active CNS metastases (or leptomeningeal disease) not controlled by prior surgery or radiotherapy. Note: Patients with treated brain metastases will be eligible if they are on a stable dose of corticosteroids or are without change in brain disease status for at least 4 weeks following related therapy (e.g., whole brain radiation, surgery). * Patients with known human immunodeficiency virus (HIV) infection. * Patients with any active infection. * Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 2 weeks prior to study entry. Note: Patients having undergone recent placement of a central venous access port will be considered eligible for enrollment if they have recovered. * Patients who have any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the test drug. * Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies. * Patients with the inability, in the opinion of the Investigator, to comply with the protocol requirements. Drugs and Other Treatments to be Excluded (Either during or within 4 weeks prior to study entry, unless otherwise noted) * Chemotherapeutic agents (standard or experimental). * Other antineoplastic agents. * Immunotherapy (including vaccines) or biological response modifier therapy. * Systemic replacement hormonal therapy for life-threatening non-oncology diseases. * Herbal preparations or related over-the-counter (OTC) preparations containing herbal ingredients (e.g., St John's Wort) during or within 2 weeks prior to study entry. * Any prior therapy with rapamycin, CCI-779, or any other rapamycin analog. * Any other experimental therapy during the course of the study. * Radiotherapy for the primary malignancy or metastases.